<DOC>
	<DOCNO>NCT02801617</DOCNO>
	<brief_summary>Aim : To demonstrate non-inferiority PRO-067 ophthalmic solution manufacture Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensor therapy subject primary open angle glaucoma ocular hypertension . Study design : muticentric , prospective , crossover ( 2x2 ) , double blind clinical study . Sample size : one hundred patient primary open angle glaucoma ocular hypertension . Patients period 1 : In first sequence 50 patient assigned receive ophthalmic solution : GAAP Ofteno ® ( latanoprost 0.005 % ) 1 drop QD 30 day second sequence 50 patient assigned receive ophthalmic solution : PRO-067 1 drop QD 30 day period . Washout period : 21 hour . Patients period 2 : pharmcological intervention change opposite therapy 30 day .</brief_summary>
	<brief_title>Non-inferiority PRO-067 Ophthalmic Solution v GAAP Ofteno® Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>The American Academy Ophthalmology Glaucoma PanelThe primary open angle glaucoma ( POAG ) progressive , chronic optic neuropathy adult intraocular pressure ( IOP ) currently unknown factor contribute damage , absence identifiable cause , characteristic acquire atrophy optic nerve loss retinal ganglion cell axon . This condition associate anterior chamber angle open gonioscopic appearance . This multicentric , crossover , double blind prospective clinical study . The investigator include patient confirm diagnosis primary open-angle glaucoma ocular hypertension , target intraocular pressure ( TIOP ) within range patient likely remain stable worsen glaucoma slow enough risk additional intervention justify . Patients randomly divide 2 group , one treat know formulation Latanoprost 0.005 % ( GAAP Ofteno® , Laboratorios Sophia , Mexico ) one treat PRO-067 ophthalmic solution . Patients receive 1 drop QD low conjunctival sac either formulation examine day : 1 , 15 , 30 , 45 ad 61 initiation treatment . A phone call security day 75 perform . Primary efficacy outcome : To evaluate efficacy PRO-067 versus GAAP Ofteno ® instill onto ocular surface subject primary open angle glaucoma ( POAG ) ocular hypertension ( HTO ) , control maintenance target intraocular pressure ( TIOP ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Female male Age : ≥18 year old Patients primary open angle glaucoma mild moderate damage ocular hypertension sufficiently control GAAP Ofteno® ( latanoprost 0.005 % ) within last 60 day Signed Informed Consent Form Subjects unique eye Subjects visual acuity &lt; 20/200 Another kind glaucoma disease different primary open angle glaucoma corneal disturbance imposibility measure intraocular pressure retinal alteration without control progressive retinal disease high risk lose vision</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Latanoprost</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Crossover study</keyword>
</DOC>